Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy
JAMA · 09.06.2026 · 335 (22) · 1959
DOI: 10.1001/jama.2026.5633 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA, erschienen am 09.06.2026. Verfasst von HCMR Investigators und 59 weiteren Autor:innen. Beteiligte Einrichtung: University of Virginia Health, Charlottesville. Hauptthemen laut MEDLINE: Arrhythmias, Cardiac, Cardiomyopathy, Hypertrophic, Death, Sudden, Cardiac. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Importance Current risk prediction guidelines for hypertrophic cardiomyopathy predict only sudden cardiac death and are imperfect, leading to avoidable deaths and unnecessary implantable cardioverter defibrillators.
Objective
To combine prospectively collected clinical history, imaging, genetic, and biomarker data to improve risk prediction of adverse events in hypertrophic cardiomyopathy. Design, Setting, and Participants A total of 2750 patients with hypertrophic cardiomyopathy were prospectively enrolled in the registry-based study from 44 sites in North America and Europe with expertise in hypertrophic cardiomyopathy and cardiac magnetic resonance (CMR) imaging. Participants were enrolled from April 1, 2014, to April 7, 2017. Exposures Patients underwent a health history questionnaire, blood sampling for biomarkers and genotyping, and contrast-enhanced CMR. Patients were followed up yearly by telephone and through records review regarding event documentation. Main Outcomes and Measures The predefined composite adjudicated primary end point was time to first event for hypertrophic cardiomyopathy–related deaths; nonfatal sustained ventricular arrhythmias (VAs) requiring cardioversion or defibrillation; and left ventricular (LV) assist device implant or heart transplant. A secondary end point was a composite of sudden cardiac death and nonfatal VA events. The elastic-net method identified the most important predictors. Cox proportional hazards regression assessed associations with time to the first end point.
Results
Of the 2750 prospectively enrolled patients, 2698 (98%) had analyzable data after 9 were excluded because they had hypertrophic cardiomyopathy phenocopies and 43 withdrew. Of these remaining patients, 1919 (71%) were male, mean age was 50 years (SD, 11 years), and 423 (16%) were from underrepresented racial and minority groups. The mean follow-up was 6.9 years (SD, 2.1 years). The primary event model in 104 patients included LV scar as a percentage of LV mass by late gadolinium enhancement (LGE%; hazard ratio [HR], 1.86; 95% CI, 1.58-2.20; P < .001), LV mass index (HR, 1.09; 95% CI, 1.01-1.17; P = .03), LV end-systolic volume index (HR, 1.28; 95% CI, 1.12-1.46; P < .001 ), all per 10-unit increase, history of heart failure at study entry (HR, 2.89; 95% CI, 1.75-4.77; P < .001), and log N-terminal pro–B-type natriuretic peptide (NT-proBNP; HR, 1.41; 95% CI, 1.17-1.70; P < .001) level per log unit, (C index for all, 0.77). An LGE percentage of the LV mass of 9% or higher substantially increased the primary composite event rate ( P = .001). The secondary sudden cardiac death and VA risk factor model (in 69 patients) included LGE%, LV mass index, LV ejection fraction, and log(NT-proBNP) (C index, 0.76). Conclusions and Relevance These results provide prospective evidence for incorporating cardiac magnetic resonance and NT-proBNP in the evaluation of patients with hypertrophic cardiomyopathy. Trial Registration ClinicalTrials.gov Identifier: NCT01915615
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Virginia Health, Charlottesville.
- MedStar Research Institute, Georgetown University, Washington, DC.
- Cleveland Clinic, Cleveland, Ohio.
- Brigham and Women's Hospital, Boston, Massachusetts.
- National Heart, Lung, and Blood Institute, Bethesda, Maryland.
- Charite´ Experimental Clinical Research Center and Helios Clinics Berlin-Buch, Berlin, Germany.
Förderung
- NHLBI NIH HHS
Zitieren
APA
HCMR Investigators, Kramer, C. M., Kolm, P., DiMarco, J. P., Desai, M. Y., Ho, C. Y., Kwong, R. Y., Dolman, S. F., Desvigne-Nickens, P., Geller, N., Kim, D. Y., Schulz-Menger, J., Friedrich, M. G., Maron, M. S., Appelbaum, E., Link, M. S., Francis, G. S., Greenberg, B., Jerosch-Herold, M., …, & Berry, C. (2026). Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy. JAMA, 335(22), 1959. https://doi.org/10.1001/jama.2026.5633
Vancouver
HCMR Investigators, Kramer CM, Kolm P, DiMarco JP, Desai MY, Ho CY, et al. Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy. JAMA. 2026;335(22):1959. doi:10.1001/jama.2026.5633
BibTeX
@article{HCMRInvestigators2026,
author = {HCMR Investigators, HCMR Investigators and Kramer, Christopher M and Kolm, Paul and DiMarco, John P and Desai, Milind Y and Ho, Carolyn Y and Kwong, Raymond Y and Dolman, Sarahfaye F and Desvigne-Nickens, Patrice and Geller, Nancy and Kim, Dong-Yun and Schulz-Menger, Jeanette and Friedrich, Matthias G and Maron, Martin S and Appelbaum, Evan and Link, Mark S and Francis, Gary S and Greenberg, Barry and Jerosch-Herold, Michael and Piechnik, Stefan and Mahmod, Masliza and Raman, Betty and Jacoby, Daniel L and Baldassare, Lauren A and White, James A and Chiribiri, Amedeo and Helms, Adam S and Choudhury, Lubna and Michels, Michelle and Bradlow, William M and Salerno, Michael and Heitner, Steven B and Masri, Ahmad and Prasad, Sanjay K and Mohiddin, Saidi A and Plein, Sven and Madias, Christopher and Mahrholdt, Heiko and Bucciarelli-Ducci, Chiara and Nightingale, Angus K and Weinsaft, Jonathan W and Kim, Han W and McCann, Gerry P and van Rossum, Albert and Germans, Tjeerd and Williamson, Eric E and Geske, Jeffrey B and Flett, Andrew S and Dawson, Dana and Mongeon, Francois-Pierre and Olivotto, Iacopo and Crean, Andrew M and Woo, Anna and Owens, Anjali T and Anderson, Lisa and Sharma, Sanjay and Biagini, Elena and Newby, David E and Andre, Florian and Berry, Colin},
title = {Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy},
journal = {JAMA},
year = {2026},
volume = {335},
number = {22},
pages = {1959},
doi = {10.1001/jama.2026.5633}
}
EUVIMED